As the coronavirus disease 2019 (Covid-19) continues to cross borders and spark global fear, scientists and pharmaceutical firms race to develop treatments and vaccines at unprecedented speed. Recently, the National Institute of Allergy and Infectious Diseases (NiAid), part of the National Institutes of Health of the United States, has sponsored the first clinical trial in the country to evaluate an experimental treatment for Covid-19 using the antiviral remdesivir, developed by Gilead Sciences. On one hand, the first batch of vaccine developed by Massachusetts-based biotechnology company, Moderna Therapeutics, was already sent to the NiAid for clinical trial.

While medicines and vaccines for treatment and prevention of Covid-19 are under investigation, the World Health Organization (WHO) recommends that people affected should receive proper care to relieve symptoms and those with serious condition should be hospitalized.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details